PETROS PHARMACEUTICALS INC (PTPI) Stock Price, Forecast & Analysis
USA - NASDAQ:PTPI - US71678J2096 - Common Stock
PTPI Key Statistics, Chart & Performance
The current stock price of PTPI is 0.0664 USD. In the past month the price decreased by -94.63%. In the past year, price decreased by -99.56%.
PTPI Latest News, Press Relases and Analysis
PTPI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 41.24 | 858.31B | ||
| JNJ | JOHNSON & JOHNSON | 18 | 450.02B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.48 | 254.34B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.97 | 242.00B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.53 | 214.40B | ||
| MRK | MERCK & CO. INC. | 9.52 | 209.46B | ||
| PFE | PFIZER INC | 7.17 | 138.16B | ||
| SNY | SANOFI-ADR | 11.24 | 119.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.95 | 92.80B | ||
| GSK | GSK PLC-SPON ADR | 7.71 | 94.17B | ||
| ZTS | ZOETIS INC | 20.01 | 55.16B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 193.71 | 42.83B |
Related stock screener links
About PTPI
Company Profile
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-12-02. The firm is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. The company also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.
Company Info
PETROS PHARMACEUTICALS INC
1185 Avenue Of The Americas, 3Rd Floor, Suite 570
New York City NEW YORK 10036 US
CEO: John D. Shulman
Employees: 21
Phone: 19732420005
PETROS PHARMACEUTICALS INC / PTPI FAQ
What does PTPI do?
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-12-02. The firm is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. The company also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.
What is the current price of PTPI stock?
The current stock price of PTPI is 0.0664 USD. The price decreased by -46.45% in the last trading session.
What is the dividend status of PETROS PHARMACEUTICALS INC?
PTPI does not pay a dividend.
What is the ChartMill technical and fundamental rating of PTPI stock?
PTPI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is PETROS PHARMACEUTICALS INC (PTPI) expected to grow?
The Revenue of PETROS PHARMACEUTICALS INC (PTPI) is expected to grow by 0.76% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is PETROS PHARMACEUTICALS INC worth?
PETROS PHARMACEUTICALS INC (PTPI) has a market capitalization of 2.07M USD. This makes PTPI a Nano Cap stock.
What is the outstanding short interest for PETROS PHARMACEUTICALS INC?
The outstanding short interest for PETROS PHARMACEUTICALS INC (PTPI) is 1.11% of its float.
PTPI Technical Analysis
PTPI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PTPI. PTPI has a bad profitability rating. Also its financial health evaluation is rather negative.
PTPI Financial Highlights
Over the last trailing twelve months PTPI reported a non-GAAP Earnings per Share(EPS) of -91.45. The EPS increased by 14.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -251.96% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTPI Forecast & Estimates
For the next year, analysts expect an EPS growth of 48.83% and a revenue growth 0.76% for PTPI